One such study observed that treatment with either recombinant p80 or with a HIF-stabilizing drug treatment that induces p80 expression suppressed IFN-γ+ Th1 and Th17 lymphocyte populations and was protective against colitis in mice [54]. This evidence concerns the gene IFNG and colitis.